Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule treatments for cancer, Zentalis focuses on targeted therapies for solid tumors. Its lead drug candidate, azenosertib (ZN-c3), is a WEE1 inhibitor designed to block a protein that helps cancer cells repair damaged DNA. The company is headquartered in San Diego, California.
Bought 6.46M
Bought 4.76M · Sold 7.50M
Granted 397.6K · Bought 888 · Sold 587.0K
Bought 725.0K · Sold 500.0K
Granted 281.8K · Bought 350 · Sold 446.4K
Granted 1.09M · Sold 16.5K
Granted 567.7K · Sold 515.9K
Granted 516.9K · Sold 20.4K
Granted 503.8K · Bought 5.0K · Sold 4.0K
Granted 405.8K · Bought 29.6K · Sold 99.0K
Granted 374.9K · Bought 21.0K
Granted 377.2K · Sold 3.4K
Granted 266.1K · Bought 21.0K · Sold 38.7K
Granted 209.3K · Bought 60.0K · Sold 5.0K
Granted 187.2K · Bought 14.2K
Granted 194.5K
Granted 158.6K · Sold 47.5K
Granted 114.2K
Granted 116.3K · Sold 10.6K
Granted 59.4K · Bought 28.5K · Sold 8.8K
Granted 52.5K
Granted 16.6K · Bought 20.0K · Sold 3.3K
Granted 52.7K · Sold 30.7K
Granted 46.6K · Sold 30.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Walters Group +2 co-filers10% owner · 1 transaction | — | 7.05M | — | 6.46M | — |
| Goel David E. +1 co-filer10% owner · 2 transactions | — | 6.46M | — | 4.76M | 7.50M |
| Sun Anthony YPresident & CEO, Director · 101 transactions | — | 4.51Mas of Apr 2022 | 397.6K | 888 | 587.0K |
| Halvorsen Ole Andreas +6 co-filers10% owner · 2 transactions | — | 3.94Mas of Dec 2020 | — | 725.0K | 500.0K |
| Bunker Kevin D.Chief Scientific Officer · 129 transactions | — | 1.72Mas of Dec 2023 | 281.8K | 350 | 446.4K |
| Paul AndreaChief Legal Officer · 5 transactions | — | 1.07Mas of Feb 2025 | 1.09M | — | 16.5K |
| Gallagher CamPresident, Interim CFO, Director · 139 transactions | — | 633.7Kas of May 2024 | 567.7K | — | 515.9K |
| Lackner MarkChief Scientific Officer · 6 transactions | — | 512.9Kas of Feb 2025 | 516.9K | — | 20.4K |
| Blackwell KimberlyChief Executive Officer, Director · 13 transactions | — | 484.1Kas of Feb 2024 | 503.8K | 5.0K | 4.0K |
| Epperly Melissa B,Chief Financial Officer · 56 transactions | — | 451.4Kas of Feb 2024 | 405.8K | 29.6K | 99.0K |
| Myers Scott DunsethDirector · 4 transactions | — | 395.9K | 374.9K | 21.0K | — |
| Hausman DianaChief Medical Officer · 3 transactions | — | 373.9Kas of May 2024 | 377.2K | — | 3.4K |
| Johnson David MichaelDirector · 17 transactions | — | 307.5K | 266.1K | 21.0K | 38.7K |
| Skvarka JanDirector · 7 transactions | — | 264.3K | 209.3K | 60.0K | 5.0K |
| Walker Luke NathanielDirector · 4 transactions | — | 201.4K | 187.2K | 14.2K | — |
| Kariuki EnochDirector · 5 transactions | — | 194.5K | 194.5K | — | — |
| Vultaggio VincentPAO and PFO · 8 transactions | — | 146.5K | 158.6K | — | 47.5K |
| Campbell ShannonDirector · 1 transaction | — | 114.2K | 114.2K | — | — |
| Brownstein CarrieChief Medical Officer · 4 transactions | — | 107.4Kas of Oct 2023 | 116.3K | — | 10.6K |
| Eastland Julia MarieCEO & President, Director · 4 transactions | — | 79.1K | 59.4K | 28.5K | 8.8K |
| Roth IrisChief Operating Officer · 1 transaction | — | 52.5Kas of Mar 2023 | 52.5K | — | — |
| Bruns IngmarChief Medical Officer · 4 transactions | — | 33.3K | 16.6K | 20.0K | 3.3K |
| Pinto AlexisChief Legal Officer · 9 transactions | — | 22.2Kas of Feb 2022 | 52.7K | — | 30.7K |
| Voliotis DimitrisSVP, Clinical Development · 16 transactions | — | 16.0Kas of Feb 2022 | 46.6K | — | 30.6K |
| Recurium Equity, LLC10% owner · 1 transaction | — | 15.0Kas of Oct 2020 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.28M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.